Your browser doesn't support javascript.
loading
1,3,4-oxadiazole/chalcone hybrids: Design, synthesis, and inhibition of leukemia cell growth and EGFR, Src, IL-6 and STAT3 activities.
Fathi, Marwa Ali A; Abd El-Hafeez, Amer Ali; Abdelhamid, Dalia; Abbas, Samar H; Montano, Monica M; Abdel-Aziz, Mohamed.
Afiliação
  • Fathi MAA; Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
  • Abd El-Hafeez AA; Pharmacology and Experimental Oncology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo 11796, Egypt; Pharmacotherapy Department, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima 734-8553, Japan; Pharmacology Department, Case Weste
  • Abdelhamid D; Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
  • Abbas SH; Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt. Electronic address: samar_hafez@mu.edu.eg.
  • Montano MM; Pharmacology Department, Case Western Reserve University School of Medicine, 10900 Euclid Avenue, Cleveland, OH 44106, USA.
  • Abdel-Aziz M; Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia 61519, Egypt.
Bioorg Chem ; 84: 150-163, 2019 03.
Article em En | MEDLINE | ID: mdl-30502626
ABSTRACT
A new series of 1,3,4-oxadiazole/chalcone hybrids was designed, synthesized, identified with different spectroscopic techniques and biologically evaluated as inhibitors of EGFR, Src, and IL-6. The synthesized compounds showed promising anticancer activity, particularly against leukemia, with 8v being the most potent. The synthesized compounds exhibited strong to moderate cytotoxic activities against K-562, KG-1a, and Jurkat leukemia cell lines in MTT assays. Compound 8v showed the strongest cytotoxic activity with IC50 of 1.95 µM, 2.36 µM and 3.45 µM against K-562, Jurkat and KG-1a leukemia cell lines, respectively. Moreover; the synthesized compounds inhibited EGFR, Src, and IL-6. Compound 8v was most effective at inhibiting EGFR (IC50 = 0.24 µM), Src (IC50 = 0.96 µM), and IL-6 (% of control = 20%). Additionally, most of the compounds decreased STAT3 activation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Chalcona / Interleucina-6 / Inibidores de Proteínas Quinases / Fator de Transcrição STAT3 / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Oxidiazóis / Chalcona / Interleucina-6 / Inibidores de Proteínas Quinases / Fator de Transcrição STAT3 / Antineoplásicos Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2019 Tipo de documento: Article